HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
MWN-AI** Summary
HUTCHMED (China) Limited has announced the initiation of a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC) targeting patients with unresectable, advanced, or metastatic solid tumors. The trial commenced on March 4, 2026, with the first patient receiving the treatment in both China and the U.S. HMPL-A580 is designed as a first-in-class therapy, combining a highly selective PI3K/PIKK inhibitor with an anti-EGFR antibody linked through a cleavable linker. This innovative approach leverages the synergy between inhibiting the PAM pathway and targeting EGFR, which is often overexpressed in various solid tumors and contributes to tumor growth and progression.
The study will evaluate HMPL-A580's safety, pharmacokinetics, immunogenicity, and preliminary efficacy across two phases. Phase I focuses on determining the maximum tolerated dose through dose escalation, while Phase IIa will further explore its safety and anti-tumor activity in specific tumor types. Preclinical data suggest that the PAM pathway inhibition enhances the efficacy of anti-EGFR treatments, with results set to be presented at a scientific conference.
HUTCHMED's ATTC platform signifies an advanced method in precision oncology, utilizing monoclonal antibodies with small-molecule inhibitors to generate synergistic anti-tumor effects and minimize off-target toxicity. This strategy aims to overcome the challenges faced by traditional treatments. The company, with over two decades of experience, is set to leverage its partnerships with major pharmaceutical firms to expedite the development of HMPL-A580 and its associated technologies in addressing significant unmet medical needs globally. HUTCHMED remains committed to translating innovations into effective treatments for cancer and related diseases.
MWN-AI** Analysis
HUTCHMED's recent initiation of a Phase I/IIa global trial for HMPL-A580 marks a significant milestone in the biotech firm’s evolution, particularly within the realm of precision oncology. Investors should take note of this event as it shines a spotlight on HUTCHMED's innovative Antibody-Targeted Therapy Conjugate (ATTC) platform, which utilizes a dual-action mechanism to tackle solid tumors via both PI3K/PIKK and EGFR pathways.
The rising incidence of solid tumors and the need for targeted therapies create a favorable market environment for HMPL-A580. With preclinical evidence suggesting superior efficacy through the novel approach of simultaneous PAM pathway and EGFR inhibition, HMPL-A580 offers the potential for a more effective treatment option compared to current therapies. Should trials support this hypothesis, HUTCHMED could carve out a unique niche, especially as the market demands more effective therapies.
However, investors should remain cognizant of the inherent risks associated with clinical trials. While HUTCHMED's established track record, including previous successful drug launches, bolsters confidence, the timeline and outcome of HMPL-A580's development remain uncertain. Critically, the firm must navigate regulatory pathways and sustain funding for trials, which can be volatile factors impacting share prices.
In the short term, investor sentiment may fluctuate based on press releases and data announcements related to HMPL-A580's trial. Inversely, positive data could catalyze significant stock appreciation. Key metrics to watch include safety, tolerability, and preliminary efficacy outcomes from initial trial phases. Given HUTCHMED's innovative framework and evolving pipeline, investors may consider this a speculative yet potentially lucrative opportunity, keeping a close watch on trial advancements in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
— Second clinical candidate from HUTCHMED’s next-generation ATTC platform —
— Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I/IIa clinical trial of HMPL-A580, HUTCHMED’s second novel Antibody-Targeted Therapy Conjugate (“ATTC”), in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first patient received the first dose on March 4, 2026.
HMPL-A580 is a first-in-class ATTC comprising a highly selective and potent PI3K/PIKK small-molecule inhibitor payload linked to an anti-EGFR antibody via a cleavable linker, HUTCHMED’s second ATTC based on this highly novel PI3K/PIKK inhibitor payload. EGFR is highly expressed in multiple types of solid tumors and is well recognized as a driving force in tumorigenesis and disease progression. Preclinical data have shown that PAM pathway inhibition synergizes with anti-EGFR therapy to enhance anti-tumor activity, and will be presented at an upcoming scientific conference.
This first-in-human Phase I/IIa, multicenter, open-label study evaluates the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HMPL-A580. The study consists of two parts. In the Phase I dose escalation part, patients will receive HMPL-A580 intravenously at predefined dose levels to determine the maximum tolerated dose and recommended dose for expansion. The subsequent Phase IIa dose expansion/?optimization part is to further characterize the safety, tolerability and preliminary anti-tumor activity of HMPL-A580 in selected solid tumors, and to determine the recommended dose for the next phase. Additional details may be found at clinicaltrials.gov, using identifier NCT07396584.
About the ATTC Platform
HUTCHMED’s ATTC platform represents a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payloads to deliver dual mechanisms of action. Unlike traditional cytotoxin-based Antibody Drug Conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in efficacy and safety.
Built on over 20 years of targeted therapy expertise, the platform enables development of drug candidates for diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve the accessibility to tumors and reduce off-tumor toxicity. This overcomes challenges of traditional small-molecule inhibitors, ensures safer long-term use, and supports combinations with chemotherapy and immunotherapy, unlocking potential for early-line treatments.
HUTCHMED has demonstrated how its partnerships leverage the expertise of multinational pharmaceutical companies to accelerate bringing novel medicines to address large unmet needs around the world, and plans to apply this strategy to its ATTC technology this year.
About the PAM Pathway and HMPL-A580
The PI3K/AKT/mTOR (“PAM”) pathway is a critical intracellular network involved in cell growth, survival, and division. Alterations in the PAM pathway are frequently associated with poor prognosis and resistance to treatment across various cancers. However, existing PAM-targeted drugs face significant challenges, including on-target toxicities that restrict dosing, feedback loops that enable pathway reactivation, and insufficient tumor-specific delivery.
By conjugating this highly novel payload to an anti-EGFR antibody, HMPL-A580 is designed to deliver targeted pathway inhibition directly into EGFR-expressing tumor cells, thereby potentially overcoming the systemic toxicity and narrow therapeutic index historically associated with PI3K/PIKK inhibitors. This approach aims to achieve deeper and more durable target inhibition while improving the overall tolerability profile.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of HMPL-A580 and other drug candidates from the ATTC platform and the further development of HMPL-A580 and other drug candidates from the ATTC platform in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support an new drug application submission of HMPL-A580 and other drug candidates from the ATTC platform in China or other jurisdictions, its potential to gain approvals from regulatory authorities on an expedited basis or at all, the efficacy and safety profile of HMPL-A580 and other drug candidates from the ATTC platform, HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for HMPL-A580 and other drug candidates from the ATTC platform and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
FAQ**
How does HUTCHMED (China) Limited HCM plan to leverage the findings from preclinical data on the PAM pathway's synergistic effects with anti-EGFR therapy for HMPL-A580 in upcoming clinical phases?
What strategies will HUTCHMED (China) Limited HCM employ to mitigate the on-target toxicities associated with traditional PAM-targeted drugs while developing HMPL-A580?
Can HUTCHMED (China) Limited HCM provide insights into the design and expected outcomes of the Phase IIa clinical trial for HMPL-A580, particularly in terms of preliminary anti-tumor activity?
How does HUTCHMED (China) Limited HCM plan to expedite the commercialization of HMPL-A580 and other ATTC candidates through its partnerships with multinational pharmaceutical companies?
**MWN-AI FAQ is based on asking OpenAI questions about HUTCHMED (China) Limited (NASDAQ: HCM).
NASDAQ: HCM
HCM Trading
1.08% G/L:
$13.99 Last:
5,324 Volume:
$13.78 Open:
